Seven abstracts on filgotinib accepted by EULAR 2017
(Thomson Reuters ONE) -
Mechelen, Belgium; 15 May 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ:
GLPG) announces the acceptance of seven abstracts from several clinical and pre-
clinical studies with the investigational agent filgotinib in rheumatoid and
psoriatic arthritis, by the Annual European Congress of Rheumatology organized
by the European League Against Rheumatism (EULAR) 2017, held in Madrid from
14-17 June. Following is a list of accepted abstracts:
"Long term safety and efficacy of filgotinib in a Phase 2b open label extension
study in patients with rheumatoid arthritis: results up to 144 weeks"
"The JAK1-selective inhibitor filgotinib reduces multiple markers of
inflammation linked to various pathologic cell types and processes in rheumatoid
arthritis patients"
"Monotherapy with the JAK1-selective inhibitor filgotinib displays an anti-
inflammatory biomarker profile in rheumatoid arthritis patients"
"The JAK1-selective inhibitor filgotinib regulates both enthesis and colon
inflammation in a mouse model of psoriatic arthritis"
"The JAK1-selective inhibitor filgotinib inhibits inflammation pathways observed
in an IL23-induced psoriatic arthritis mouse model"
"Effects of the JAK1-selective inhibitor filgotinib on multibiomarker disease
activity scores in patients with active rheumatoid arthritis and an inadequate
response to methotrexate"
"Effect of baseline serum CRP levels on clinical efficacy in rheumatoid
arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b
studies"
All abstracts are available on the website of the EULAR 2017 Congress.
Filgotinib is an investigational drug and its efficacy and safety have not been
established.
For information about the studies with filgotinib: www.clinicaltrials.gov
For more information about filgotinib: www.glpg.com/filgotinib
About filgotinib
Galapagos and Gilead entered into a global collaboration for the development and
commercialization of filgotinib in inflammatory indications. Following the Phase
2 DARWIN and FITZROY results, filgotinib is currently being investigated in the
FINCH Phase 3 program in rheumatoid arthritis, the DIVERSITY Phase 3 program in
Crohn's disease and in the SELECTION Phase 2b/3 study in ulcerative colitis.
Furthermore, filgotinib is being studied in Phase 2 studies for small bowel and
fistulizing Crohn's disease, cutaneous lupus erythematosus (CLE), Sjögren's
syndrome, ankylosing spondylitis (TORTUGA), and psoriatic arthritis (EQUATOR).
About EULAR
The European League Against Rheumatism (EULAR) is the organization which
represents the patient, health professional and scientific societies of
rheumatology of all the European nations. EULAR endeavors to stimulate, promote,
and support the research, prevention, treatment and rehabilitation of rheumatic
diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic
diseases of the connective tissue, locomotor and musculoskeletal systems.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-
clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and developed
filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 530 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More information at www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Director Communications
Communications +31 6 53 591 999
+1 781 460 1784 communications(at)glpg.com
Paul van der Horst
Director IR & Business Development
+31 6 53 725 199
ir(at)glpg.com
Forward-Looking Statements
This release may contain forward-looking statements, including statements
regarding Galapagos' strategic ambitions, the anticipated timing of clinical
studies with filgotinib and the progression and results of such studies.
Galapagos cautions the reader that forward-looking statements are not guarantees
of future performance. Forward-looking statements involve known and unknown
risks, uncertainties and other factors which might cause the actual results,
financial condition and liquidity, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in differences
are the inherent uncertainties associated with competitive developments,
clinical trial and product development activities and regulatory approval
requirements (including that data from the ongoing and planned clinical research
programs may not support registration or further development of filgotinib due
to safety, efficacy or other reasons), Galapagos' reliance on collaborations
with third parties (including its collaboration partner for filgotinib, Gilead),
and estimating the commercial potential of Galapagos' product candidates. A
further list and description of these risks, uncertainties and other risks can
be found in Galapagos' Securities and Exchange Commission (SEC) filings and
reports, including in Galapagos' most recent annual report on form 20-F filed
with the SEC and subsequent filings and reports filed by Galapagos with the SEC.
Given these uncertainties, the reader is advised not to place any undue reliance
on such forward-looking statements. These forward-looking statements speak only
as of the date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based or that
may affect the likelihood that actual results will differ from those set forth
in the forward-looking statements, unless specifically required by law or
regulation.
Filgotinib at EULAR:
http://hugin.info/133350/R/2104898/798855.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.05.2017 - 22:00 Uhr
Sprache: Deutsch
News-ID 544076
Anzahl Zeichen: 8210
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Seven abstracts on filgotinib accepted by EULAR 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
